$CLPT earnings report

ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million. AlphAI read ClearPoint Neuro's third quarter 2026 filing as mixed.

third quarter 2026

AlphAI · Earnings readCLPT · third quarter 2026 · ended September 30, 2026

ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million

→Mixed quarter

Revenue growth accelerated to 36%, led by neurosurgery navigation and therapy and capital equipment and software, but gross margin declined, operating expenses increased, and the Company reported a wider net loss.

Revenue
$12.1M
36% y/y
Biologics and drug delivery revenue
$4.9M
11% y/y
Gross margin · GAAP
58%
EPS · GAAP
$ (0.24 )
2026 outlook
$48.0 million and $50.0 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$12.1M–36%
Product revenue, three months ended September 30, 2026GAAP$7.89M––
Service and other revenue, three months ended September 30, 2026GAAP$4.18M––
Cost of revenue, three months ended September 30, 2026GAAP$5.02M––
Gross profit, three months ended September 30, 2026GAAP$7.06M––
Gross margin, three months ended September 30, 2026GAAP58%––
Research and development costs, three months ended September 30, 2026GAAP$4.02M––
Sales and marketing expenses, three months ended September 30, 2026GAAP$5.53M––
General and administrative expenses, three months ended September 30, 2026GAAP$3.84M––
Operating expenses, three months ended September 30, 2026GAAP$13.4M–23%
Operating loss, three months ended September 30, 2026GAAP−$6.33M––
Other income (expense), net, three months ended September 30, 2026GAAP$22K––
Interest income, three months ended September 30, 2026GAAP$292K––
Interest expense, three months ended September 30, 2026GAAP−$1.45M––
Net loss before income taxes, three months ended September 30, 2026GAAP−$7.46M––
Income tax (benefit) expense, three months ended September 30, 2026GAAP−$4K––
Net loss, three months ended September 30, 2026GAAP−$7.46M––
Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP$ (0.24 )––
Weighted average shares outstanding, basic and diluted, three months ended September 30, 2026GAAP30,983,193––
Total revenue, nine months ended September 30, 2026GAAP$35.08M––
Product revenue, nine months ended September 30, 2026GAAP$24.07M––
Service and other revenue, nine months ended September 30, 2026GAAP$11.01M––
Gross profit, nine months ended September 30, 2026GAAP$21.52M––
Operating loss, nine months ended September 30, 2026GAAP−$25.05M––
Net loss, nine months ended September 30, 2026GAAP−$28.35M––
Net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP$ (0.94 )––
Net cash used in operating activities, nine months ended September 30, 2026GAAP−$20.09M––
Net cash used in investing activities, nine months ended September 30, 2026GAAP−$996K––
Net cash provided by financing activities, nine months ended September 30, 2026GAAP$21.23M––

Segments

SegmentRevenueq/qy/y
Biologics and drug delivery revenueThe increase is primarily attributable to higher revenue from services performed at ClearPoint Advanced Laboratories.$4.9M–11%
Neurosurgery navigation and therapy revenueThe increase is driven primarily by additional revenues due to sales of the IRRA flow product, which the Company acquired in connection with its acquisition of IRRAS in the fourth quarter of 2025.$5.4M–59%
Capital equipment and software revenueGrowth was primarily due to an increase in placements of ClearPoint navigation capital and software, IRRA flow control units, and Prism laser units.$1.7M–68%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 outlook

  • Revenue$48.0 million and $50.0 million

Capital returns

  • Proceeds from issuance of common stock under at-the-market equity offering program, net of issuance costs of $0.5 million: $ 22,020 (in thousands)

What drove it

  • Total revenue increased $3.2 million, or 36%, driven by growth across biologics and drug delivery, neurosurgery navigation and therapy, and capital equipment and software.
  • Management said revenue growth outpaced operating expense growth of 23% as completion of the IRRA flow product integration enabled improved operating leverage.
  • The Company reported that one partner submitted its first formal BLA for the treatment of Huntington's Disease.
  • ClearPoint is an industry partner in a five-year, $2.98 million competitively awarded NCI R01 led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases.

Concerns

  • Gross margin was 58%, compared with 63% in the same period in 2025, due primarily to overhead costs at the new ClearPoint Advanced Laboratories facility and additional amortization expense of acquired intangible assets.
  • Operating expenses increased 23%, mainly due to the IRRAS acquisition in November 2025, including higher personnel costs, occupancy costs, and travel costs.
  • Net loss was $ (7,460 ) (in thousands), compared with $ (5,891 ) (in thousands) in the same period in 2025.
  • Net cash used in operating activities was $ (20,094 ) (in thousands) for the nine months ended September 30, 2026.
  • Interest expense was $ (1,446 ) (in thousands) for the three months ended September 30, 2026, compared with $ (939 ) (in thousands) in the same period in 2025.

What to watch

  • Execution against 2026 revenue guidance of $48.0 million and $50.0 million.
  • Adoption and growth of neurosurgery navigation and therapy products, including IRRA flow and laser therapy.
  • Growth of biologics and drug delivery business, including preclinical services at ClearPoint Advanced Laboratories.
  • The timing and outcome of biologics and drug delivery partners' clinical trials and regulatory submissions.
  • The integration of acquired businesses, including IRRAS.

Balance sheet and cash flow

  • Cash and cash equivalents were $46.2 million as of September 30, 2026, compared with $45.9 million at December 31, 2025.
  • Long-term notes payable, net: $ 50,840 (in thousands) at September 30, 2026, compared with $ 49,077 (in thousands) at December 31, 2025.
  • Cash, cash equivalents and restricted cash, end of period: $ 47,110 (in thousands) for the nine months ended September 30, 2026, compared with $ 38,401 (in thousands) for the nine months ended September 30, 2025.
  • Purchases of property and equipment: $ (996 ) (in thousands) for the nine months ended September 30, 2026, compared with $ (473 ) (in thousands) for the nine months ended September 30, 2025.
  • Net change in cash, cash equivalents and restricted cash: $ 137 (in thousands) for the nine months ended September 30, 2026, compared with $ 18,297 (in thousands) for the nine months ended September 30, 2025.

Analysis

ClearPoint Neuro reported third-quarter revenue of $12.1 million, up 36% from $8.9 million in the same period in 2025. Revenue growth was broad across the operating categories discussed in the release. Neurosurgery navigation and therapy increased 59% to $5.4 million, biologics and drug delivery increased 11% to $4.9 million, and capital equipment and software increased 68% to a record $1.7 million. The IRRA flow portfolio was a major contributor to navigation and therapy growth, while higher services performed at ClearPoint Advanced Laboratories supported biologics and drug delivery revenue.

The quarter showed improved top-line momentum but weaker gross profitability. Gross margin declined to 58% from 63%, with the Company citing overhead costs at the new ClearPoint Advanced Laboratories facility and additional amortization of acquired intangible assets. Operating expenses increased 23% to $13.4 million, principally reflecting the November 2025 IRRAS acquisition, higher clinical and sales personnel costs, occupancy costs, and travel costs. The result was an operating loss of $ (6,332 ) (in thousands), compared with $ (5,276 ) (in thousands) in the prior-year quarter, and a net loss of $ (7,460 ) (in thousands), compared with $ (5,891 ) (in thousands).

Liquidity was supported by equity financing. Cash and cash equivalents were $46.2 million at September 30, 2026, compared with $45.9 million at December 31, 2025. The Company received net proceeds of $22.0 million from its at-the-market equity offering program, which partly offset $ (20,094 ) (in thousands) of net cash used in operating activities during the first nine months of 2026. Long-term notes payable, net, were $ 50,840 (in thousands) at September 30, 2026.

The Company now estimates 2026 revenue of between $48.0 million and $50.0 million. Investors will be focused on whether continued IRRA flow sales, capital placements, and ClearPoint Advanced Laboratories services can sustain revenue growth while the Company works to improve the 58% gross margin and contain operating cash use. Other reported operational developments include a first formal BLA submitted by one partner for Huntington's Disease and ClearPoint's participation in a five-year, $2.98 million NCI R01 supporting MR-guided laser therapy for spinal metastases.

Management, verbatim

Throughout 2026 we have continued to make substantial strategic progress in building our comprehensive drug delivery ecosystem, adding new biopharma partners, and assisting existing partners progress through the regulatory process globally.

Joe Burnett, President and CEO at ClearPoint Neuro

The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth.

Joe Burnett, President and CEO at ClearPoint Neuro

The 36% revenue growth outpaced operating expense growth of 23% in the third quarter, as the completion of the IRRA flow product integration has enabled improved operating leverage.

Joe Burnett, President and CEO at ClearPoint Neuro

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported quarterly metrics
  • Quarterly operating cash flow
  • Free cash flow
  • Share repurchases
  • Dividends
  • Non-GAAP financial measures
  • Gross margin guidance
  • Operating expense guidance
  • Tax-rate guidance
  • Previous-release outlook needed to assess actual results versus prior guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CLPT earnings dates

When is ClearPoint Neuro's next earnings date?
AlphAI has no date for CLPT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.